drugset

drugset / Trial / NCT00725426

Effect of Rifampin on Bosutinib When Both Are Given to Healthy People

NCT00725426 ↗

Phase 1 Completed 24 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

Non-randomizedSingle-groupOpen-label

Summary

Study to examine whether rifampin has an effect on the pharmacokinetics of bosutinib.

Timeline

Start: 2008-07
Primary completion: 2008-08
Completion: 2008-08

Publications

Abbas R, Boni J, Sonnichsen D. Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects. Drug Metab Pers Ther. 2015 Mar;30(1):57-63. doi: 10.1515/dmdi-2014-0026.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bosutinib	Small molecule	500 mg	Oral

Indications

No indication recorded.